| 4 Small Cap Biotechs To Keep an Eye On The Inflection Point submits: Biotech stocks are a long-time favorite of investors, especially during bear markets, due to their catalytic nature which tends to be resistant to the vagaries of the macro-economic climate. With this in mind, we have been tracking a number of biotech companies with the potential for positive FDA decisions in the coming weeks and months. Should any of these companies receive FDA approval, their stocks should see substantial moves to the upside. Here are a few of our most compelling ideas in the biotech space: Affymax Inc. (AFFY)Complete Story » seekingalpha.com |
Peregrine Pharmaceuticals: Good Long Term Potential VFC submits: It's been a while since I've mentioned Peregrine Pharmaceuticals (PPHM), but I thought that the highs of April and May were a better time to sell than accumulate, so I left it alone. The mini-run earlier this year was based on a flurry of Press Releases outlining encouraging results from the ongoing Phase II trials that were to be presented at ASCO. Now that the hype has died down a bit and the stock is back to trading for around three dollars, Peregrine Pharmaceuticals may be worth a look as a "Phase II accumulation" pick, with eyes towards the conclusion of the ongoing trials and the future potential of both Bavituximab and Cotara. Complete Story » seekingalpha.com |
Kendall Law Group Investigates Enzo Biochem Inc. for Shareholders (Business Wire) DALLAS----Kendall Law Group, a national securities firm led by a former federal judge Joe Kendall with attorneys that include a former U.S. Attorney, is investigating Enzo Biochem Inc. for shareholders. us.rd.yahoo.com |
Array BioPharma to Present at the Rodman & Renshaw Global Investment Conference and the Stifel Nicolaus Healthcare Conference [Business Wire] - BOULDER, Colo.----Array BioPharma Inc. today announced that its Chief Executive Officer, Robert E. Conway, will speak at the Rodman & Renshaw Global Investment Conference and the Stifel Nicolaus Healthcare Conference. us.rd.yahoo.com |
New York City Audience Applauds Speech By Cannabis Science CEO Dr. Robert Melamede at 'The Marijuana Conference;' CFO Richard Cowan on Panel Moderated by CNBC Anchor Trish Regan for New Program to Air In Early December Also Covered By Disco [PR Newswire] - Cannabis Science, Inc. , a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to report that the audience at "the first non-biased event in the industry" loudly cheered the speech by Cannabis Science CEO Dr. us.rd.yahoo.com |